Effect of glomerular filtration rate impairment on diagnostic performance of neutrophil gelatinase-associated lipocalin and B-type natriuretic peptide as markers of acute cardiac and renal failure in chronic kidney disease patients

Critical Care

Volumn 18, Issue 1, 2014, Pages

  Donadio, Carlo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PENTETIC ACID TECHNETIUM 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CONCENTRATING CAPACITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINARY EXCRETION; VERY ELDERLY; YOUNG ADULT; BLOOD; CHRONIC KIDNEY FAILURE; HEART FAILURE; LABORATORY DIAGNOSIS; URINE;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FALSE POSITIVE REACTIONS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; LIPOCALINS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROTO-ONCOGENE PROTEINS; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84898596787     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13752     Document Type: Article

References (45)

1. Silverberg DS, Wexler D, Blum M, Wollman Y, Schwartz D, Sheps D, Keren G, Iaina A. The interaction between heart failure, renal failure and anemia: the cardio-renal syndrome. Blood Purif 2004, 22:277-284. 10.1159/000078698, 15166489.
2. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008, 10:997-1000. 10.1016/j.ejheart.2008.07.001, 18804416.
3. Cruz DN, de Cal M, Garzotto F, Perazella MA, Lentini P, Corradi V, Piccinni P, Ronco C. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010, 36:444-451. 10.1007/s00134-009-1711-1, 2820221, 19956925.
4. Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, Clopton P, van Veldhuisen DJ. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011, 13:846-851. 10.1093/eurjhf/hfr087, 3143832, 21791540.
5. Alvelos M, Lourenço P, Dias C, Amorim M, Rema J, Leite AB, Guimarães JT, Almeida P, Bettencourt P. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol 2013, 165:51-55. 10.1016/j.ijcard.2011.07.080, 21872946.
6. Niizuma S, Iwanaga Y, Yahata T, Tamaki Y, Goto Y, Nakahama H, Miyazaki S. Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. Clin Chem 2009, 55:1347-1353. 10.1373/clinchem.2008.121236, 19460838.
7. Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004, 50:1071-1074. 10.1373/clinchem.2003.030692, 15161726.
8. Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol 2010, 133:14-23. 10.1309/AJCP60HTPGIGFCNK, 20023254.
9. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012, 50:1505-1517.
10. McIlroy DR, Wagener G, Lee HT. Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol 2010, 5:211-219. 10.2215/CJN.04240609, 2827603, 20056755.
11. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266. National Kidney Foundation.
12. Bianchi C, Bonadio M, Donadio C, Tramonti G, Figus S. Measurement of glomerular filtration rate in man using DTPA-99mTc. Nephron 1979, 24:174-178. 10.1159/000181711, 492428.
13. Bianchi C, Donadio C, Tramonti G. Noninvasive methods for the measurement of total renal function. Nephron 1981, 28:53-57. 10.1159/000182104, 7027061.
14. Cullen MR, Murray PT, Fitzgibbon MC. Establishment of a reference interval for urinary neutrophil gelatinase-associated lipocalin. Ann Clin Biochem 2012, 49:190-193. 10.1258/acb.2011.011105, 22323662.
15. Clinical and Laboratory Standards Institute Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. CLSI Document C28-A3 2008, Wayne, PA: CLSI, 3, Clinical and Laboratory Standards Institute.
16. Meng X-L, Rosenthal R, Rubin DB. Comparing correlated correlation coefficients. Psychol Bull 1992, 111:172-175.
17. Bossuyt PM, Reitsma JB, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003, 326:41-44. 10.1136/bmj.326.7379.41, 1124931, 12511463.
18. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Hystochem J 1999, 31:433-441.
19. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997, 45:17-23. 10.1006/geno.1997.4896, 9339356.
20. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007, 18:407-413. 10.1681/ASN.2006080882, 17229907.
21. Grigoryev DN, Liu M, Hassoun HT, Cheadle C, Barnes KC, Rabb H. The local and systemic inflammatory transcriptome after acute kidney injury. J Am Soc Nephrol 2008, 19:547-558. 10.1681/ASN.2007040469, 2391061, 18235097.
22. Paragas N, Qiu A, Zhang Q, Samstein B, Deng S-X, Schmidt-Ott KM, Viltard M, Yu W, Forster CS, Gong G, Liu Y, Kulkarni R, Mori K, Kalandadze A, Ratner AJ, Devarajan P, Landry DW, D'Agati V, Lin C-S, Barasch J. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011, 17:216-222. 10.1038/nm.2290, 3059503, 21240264.
23. Pickering JW, Endre ZH. The clinical utility of plasma neutrophil gelatinase-associated lipocalin in acute kidney injury. Blood Purif 2013, 35:295-302. 10.1159/000351542, 23712081.
24. Donadio C. Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary β-trace protein. Am J Physiol Renal Physiol 2010, 299:F1407-F1423. 10.1152/ajprenal.00507.2009, 20844024.
25. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. NGAL Meta-analysis investigator group: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54:1010-1024.
26. Breidthardt T, Christ-Crain M, Stolz D, Bingisser R, Drexler B, Klima T, Balmelli C, Schuetz P, Haaf P, Schärer M, Tamm M, Müller B, Müller C. A combined cardiorenal assessment for the prediction of acute kidney injury in lower respiratory tract infections. Am J Med 2012, 125:168-175. 10.1016/j.amjmed.2011.07.010, 22269620.
27. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:337-344. 10.2215/CJN.03530708, 2637601, 19176795.
28. Malyszko J, Bachorzewska-Gajewska H, Sitniewska E, Malyszko JS, Poniatowski B, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease. Ren Fail 2008, 30:625-628. 10.1080/08860220802134607, 18661413.
29. Malyszko J, Malyszko JS, Mysliwiec M. Serum neutrophil gelatinase-associated lipocalin correlates with kidney function in renal allograft recipients. Clin Transplant 2009, 23:681-686. 10.1111/j.1399-0012.2009.01034.x, 19708926.
30. Fu WJ, Xiong SL, Fang YG, Wen S, Chen ML, Deng RT, Zheng L, Wang SB, Pen LF, Wang Q. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine 2012, 41:82-88. 10.1007/s12020-011-9509-7, 21779943.
31. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, Buemi M. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009, 32:91-98. 10.1159/000209379, 19321980.
32. Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, Rossing P. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 2011, 79:1113-1118. 10.1038/ki.2010.554, 21270761.
33. Nielsen SE, Reinhard H, Zdunek D, Hess G, Gutiérrez OM, Wolf M, Parving HH, Jacobsen PK, Rossing P. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 2012, 97:71-76. 10.1016/j.diabres.2012.02.007, 22402306.
34. Abouchacra S, Chaaban A, Hakim R, Gebran N, El-Jack H, Rashid F, Boobes Y, Muhairi A, Hussain Q, Khan I, Chedid F, Negelkerke N. Renal biomarkers for assessment of kidney function in renal transplant recipients: how do they compare?. Int Urol Nephrol 2012, 44:1871-1876. 10.1007/s11255-012-0188-y, 22639068.
35. Szewczyk M, Wielkoszyński T, Zakliczyński M, Zembala M. Plasma neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine, and glomerular filtration rate in patients after heart and lung transplantation. Transplant Proc 2009, 41:3242-3243. 10.1016/j.transproceed.2009.08.018, 19857721.
36. Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 2009, 36:45-51. 10.1007/s12020-009-9187-x, 19390997.
37. Abraham BP, Frazier EA, Morrow WR, Blaszak RT, Devarajan P, Mitsnefes M, Bryant JC, Sachdeva R. Cystatin C and neutrophil gelatinase-associated lipocalin as markers of renal function in pediatric heart transplant recipients. Pediatr Transplant 2011, 15:564-569.
38. Breidthardt T, Socrates T, Drexler B, Noveanu M, Heinisch C, Arenja N, Klima T, Züsli C, Reichlin T, Potocki M, Twerenbold R, Steiger J, Mueller C. Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure. Crit Care 2012, 16:R2. 10.1186/cc10600, 3396227, 22226205.
39. Di Somma S, Magrini L, De Berardinis B, Marino R, Ferri E, Moscatelli P, Ballarino P, Carpinteri G, Noto P, Gliozzo B, Paladino L, Di Stasio E. Additive value of blood neutrophil gelatinase-associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department. Crit Care 2013, 17:R29. 10.1186/cc12510, 23402494.
40. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001, 276:37258-37265. 10.1074/jbc.M106089200, 11486009.
41. Nejat M, Hill JV, Pickering JW, Edelstein CL, Devarajan P, Endre ZH. Albuminuria increases cystatin C excretion: implications for urinary biomarkers. Nephrol Dial Transplant 2012, 27:iii96-iii103.
42. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney int 2007, 71:967-970. 10.1038/sj.ki.5002165, 17342180.
43. Racek J, Kralova H, Trefil L, Rajdl D, Eiselt J. Brain natriuretic peptide and N-terminal proBNP in chronic hemodialysis patients. Nephron Clin Prat 2006, 103:c162-c172.
44. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007, 71:548-554. 10.1038/sj.ki.5002087, 17299526.
45. van den Kerkhof JJ, Van der Sande FM, Leunissen K, Kooman JP. Are natriuretic peptides useful biomarkers in dialysis patients?. Perit Dial Int 2007, 27:636-640.